Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20796458 | 0.79 | ARF6 (1.00) | ARF6 | |
| SCHEMBL15121544 | 0.79 | ARF6 (0.41) | ARF6PLAT | |
| SCHEMBL20796484 | 0.77 | ARF6 (1.00) | ARF6 | |
| SCHEMBL257412 | 0.76 | TP53 (0.42) | ARF6 | |
| SCHEMBL256944 | 0.73 | PLAT (0.51) | ARF6PLAT | |
| Pyrimidine SCHEMBL15020692 | 0.72 | ARF6 (0.37) | ARF6 | |
| SCHEMBL20796486 | 0.72 | ARF6 (1.00) | ARF6 | |
| SCHEMBL10072120 | 0.71 | ARF6 (0.53) | ARF6PLAT | |
| SCHEMBL20796202 | 0.71 | ARF6 (1.00) | ARF6 | |
| SCHEMBL20796451 | 0.71 | ARF6 (0.83) | ARF6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103153999-B | Compounds as cannabinoid receptor-1 inhibitors | AMOREPACIFIC CORP. (KR) | 2016-06-01 | — | — | CN | disclosed |
| US-8975264-B2 | Compound acting as a cannabinoid receptor-1 inhibitor | AMOREPACIFIC CORPORATION (KR) | 2015-03-10 | — | — | US | disclosed |
| US-8975264-B2 | Compound acting as a cannabinoid receptor-1 inhibitor | AMOREPACIFIC CORPORATION (KR) | 2015-03-10 | — | — | US | disclosed |
| EP-2617723-A2 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | Amorepacific Corporation (KR) | 2013-07-24 | — | — | EP | disclosed |
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | AMOREPACIFIC CORPORATION (KR) | 2013-06-20 | — | — | US | disclosed |
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | AMOREPACIFIC CORPORATION (KR) | 2013-06-20 | — | — | US | disclosed |
| CN-103153999-A | Novel compounds as cannabinoid receptor-1 inhibitors | AMOREPACIFIC CORP | 2013-06-12 | — | — | CN | disclosed |
| WO-2012030170-A2 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | (주)아모레퍼시픽 (KR) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | CNR1, CNR2, GPR18 | ARF6 1261/4885PLAT 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.